Danish biotech firm Genmab (OMX: GEN) has a third member of its executive team.
Judith Klimovsky will start as chief development officer next week, joining its executive team which currently comprises of chief executive, Jan van de Winkel, and finance boss, David Eatwell.
"With Judith heading our product development efforts, we will be able to bring forward truly differentiated products"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze